Examination of the effectiveness of bepotastine besilate administration to the inducer and itching of atopic dermatitis patients

Examination of the effectiveness of bepotastine besilate administration to the inducer and itching of atopic dermatitis patients - Examination of the effectiveness of bepotastine besilate administration to the inducer and itching of atopic dermatitis patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000012187

Enrollment

Registered

2013-11-01

Start date

2013-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

atopic dermatitis

Interventions

The administration of the Tarion 10mg / 2 times / day: 4 weeks from the start of the study (Increase or decrease accordingly 20mg 2 minutes)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: &middot; (Itching and VAS> 30) patients who do not itch disappearance of the only topical steroid in adult atopic dermatitis. &middot; It is 20 years of age or older. &#8226; After you have received a sufficient explanation to study entry, document consent free will of the patient himself has been obtained on a thorough understanding.

Exclusion criteria

Exclusion criteria: Atopic dermatitis patients with severe for example Cases it is necessary to continue using drugs that seem to affect the response evaluation of test agent within a week before, antiallergic agents, antihistamines, oral steroids, and cyclosporine oral medicine. Patients having serious complications liver disease, kidney disease, heart disease, and other attending physician deems inappropriate. Dialysis patients and patients taking opioid be assumed pruritus central. Potential cases of lactating women, pregnant or are pregnant. Other patients attending physician deems inappropriate incorporation into the study.

Design outcomes

Primary

Measure	Time frame
QOL (Dermatology Life Quality Index) Pruritus (Visual Analog Scale) Safety and sleepiness (Visual Analog Scale) Severity (day skin simplified method) before Administered / after 2 weeks / 4 weeks	—

Secondary

Measure	Time frame
Tryptase Cortisol TARC before Administered / after 2 weeks / 4 weeks	—

Countries

Japan

Contacts

Public ContactTakasuke Ogawa

Juntendo university hospital Departoment of dermatorogy

t-ogawa@juntendo.ac.jp03-3813-311

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026